Efficacy of the AkkoLens IOL in Patients With Cataract

Launched by VISSUM, INSTITUTO OFTALMOLÓGICO DE ALICANTE · Jan 26, 2024

Keywords

ClinConnect Summary

This is an observational, prospective, longitudinal, and consecutive study involving patients with clinical cataract eligible for cataract surgery who opt for the implantation of the Lumina (Akkolens, Clinical BV, The Netherlands) accommodative lens. The study was conducted at the Cornea, Cataract, and Refractive Surgery Unit in Vissum Alicante, Miranza Group, Spain. The study adhered to the tenets of the Declaration of Helsinki (2013 version )and was approved by the Comite Etico de Investigacion Clinica Vissum Alicante.

The study group included 50 eyes of 25 patients, aged 40 to 81 years ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Visual significant cataract with an expected positive effect of the surgery on the visual outcome.
• • ≥ 40 years of age
• • Calculated IOL power within the available diopter range
• Exclusion Criteria:
• • Comorbidities causing postoperative visual impairment, such as degenerative macular pathology
• • Glaucoma with optic disk damage and visual field loss
• • Retinal dystrophies
• • Previous ocular surgeries, such as vitrectomy, corneal graft surgery
• • Lens subluxation
• • Significant eye trauma that may induce lens instability
• • Congenital ocular anomalies
• • Endothelial cell count \< 1200 cells/mm2
• • Previous known reading disabilities, such as dyslexia.